Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PRBOY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Alb-DMBA-SIL-DOX
|
|||||
| Synonyms |
Alb DMBA SIL DOX
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Oral squamous cell carcinoma [ICD11:2B6E]
Investigative
Thyroid cancer [ICD11:2D10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
0.12
|
|||||
| Structure |
|
|||||
| Antibody Name |
Alb
|
Antibody Info | ||||
| Antigen Name |
Albumin (ALB)
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
DMBA-SIL
|
Linker Info | ||||
| Conjugate Type |
Maleimide selectively reacts with free thiol at Cys 34 on Alb, Michael addition.
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
21.41 nM
|
|||
| Method Description |
The inhibitory activity of Alb-DMBA-SIL-DOX against cancer cell growth was evaluated in various human cancer cell lines in vitro. Caged and conjugated DOX is selectively cytotoxic and activated by X-ray irradiation.
|
||||
| In Vitro Model | Acute erythroid leukemia | TBP-3743 cancer cells | Mus musculus | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
35.57 nM
|
|||
| Method Description |
The inhibitory activity of Alb-DMBA-SIL-DOX against cancer cell growth was evaluated in various human cancer cell lines in vitro. Caged and conjugated DOX is selectively cytotoxic and activated by X-ray irradiation.
|
||||
| In Vitro Model | Thyroid gland anaplastic carcinoma | 8505C cells | CVCL_1054 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
52.13 nM
|
|||
| Method Description |
The inhibitory activity of Alb-DMBA-SIL-DOX against cancer cell growth was evaluated in various human cancer cell lines in vitro. Caged and conjugated DOX is selectively cytotoxic and activated by X-ray irradiation.
|
||||
| In Vitro Model | Mouse colon adenocarcinoma | MC-38 cells | CVCL_B288 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
224.40 nM
|
|||
| Method Description |
The inhibitory activity of Alb-DMBA-SIL-DOX against cancer cell growth was evaluated in various human cancer cell lines in vitro. Caged and conjugated DOX is selectively cytotoxic and activated by X-ray irradiation.
|
||||
| In Vitro Model | Oral cavity squamous cell carcinoma | MOC-L2 cells | CVCL_A9X4 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.